givinostat
Selected indexed studies
- Givinostat: First Approval. (Drugs, 2024) [PMID:38967716]
- Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet Neurol, 2024) [PMID:38508835]
- Givinostat. (, 2006) [PMID:39999255]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Givinostat: First Approval. (2024) pubmed
- Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2024) pubmed
- Givinostat. (2006) pubmed
- Histological effects of givinostat in boys with Duchenne muscular dystrophy. (2016) pubmed
- Givinostat Oral Suspension. (2024) pubmed
- Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons. (2025) pubmed
- Givinostat: an emerging treatment for polycythemia vera. (2020) pubmed
- Givinostat Hydrochloride. (2024) pubmed
- Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. (2013) pubmed
- Safety and Efficacy of Givinostat for Patients with Muscular Dystrophy: A Systematic Review. (2025) pubmed